Shilpa Biologicals has launched its new PartnerPower, a purpose-built digital transparency platform that it describes as giving customers "uninterrupted, real-time insights into every stage of their biologics development and manufacturing programmes."
The platform has been designed to replace periodic reporting with a continuously live, collaborative environment — which the company said would enable biopharmaceutical innovators worldwide to monitor the true "state of affairs" of their projects any time, anywhere.
PartnerPower will deliver real-time visibility into process development laboratories and GMP manufacturing environments, providing sponsors with access to operational data as it is generated.
Shilpa argues that through linking information across R&D, analytical development and manufacturing operations, the platform will allow closer coordination, faster decision-making and more efficient technology transfer.
The launch is part of the company's wider strategy to "elevate the global CDMO experience from transactional outsourcing to a fully integrated, partnership-driven model."
The platform aligns with global regulatory authorities' expectations for data integrity and confidentiality, enabling a continuous state of audit readiness.
Madhav Bhutada, Director, Shilpa Biologicals, said: "With PartnerPower, we are setting a new global benchmark for what transparency in a CDMO partnership should look like."
It allows our sponsors to innovate with complete confidence, knowing that every data point, every decision and milestone is visible to them in real time.
The Shilpa Biologicals team will be exhibiting at BIO San Diego this year, at booth #3351.
